2. Academic Validation
  3. Protocol to utilize fresh uncultured human lung tumor cells for personalized functional diagnostics

Protocol to utilize fresh uncultured human lung tumor cells for personalized functional diagnostics

  • STAR Protoc. 2022 Sep 26;3(4):101720. doi: 10.1016/j.xpro.2022.101720.
Sarang S Talwelkar 1,  Iris A K Lähdeniemi 2,  Mikko I Mäyränpää 3,  Annabrita Hemmes 2,  Nora Linnavirta 2,  Jari Räsänen 4,  Aija Knuuttila 5,  Krister Wennerberg 6,  Emmy W Verschuren 7
Affiliations

Affiliations

  • 1 Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Institute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku 20520, Finland.
  • 2 Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
  • 3 Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • 4 Department of Thoracic Surgery, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
  • 5 Department of Pulmonary Medicine, Heart and Lung Center and Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • 6 Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00014 Helsinki, Finland; BRIC - Biotech Research & Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark. Electronic address: krister.wennerberg@bric.ku.dk.
  • 7 Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00014 Helsinki, Finland. Electronic address: emmy.verschuren@helsinki.fi.
PMID: 36170112 DOI: 10.1016/j.xpro.2022.101720
Abstract

Drug sensitivity data acquired from solid tumor-derived cultures are often unsuitable for personalized treatment guidance due to the lengthy turnaround time. Here, we present a protocol for determining ex vivo drug sensitivities using fresh uncultured human lung tumor-derived EpCAM+ epithelial cells (FUTCs). We describe steps for drug testing in FUTCs to identify tumor cell-selective single or combination therapy in 72 h of sample processing. The FUTC-based approach can also be used to predict in vivo resistance to known targeted therapies. For complete details on the use and execution of this protocol, please refer to Talwelkar et al. (2021).

Keywords

Cancer; Cell biology; Cell isolation; Cell-based assays; Clinical protocol; Health sciences; High throughput screening.

Figures
Products